TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04144309

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture (EA) and Auricular Acupressure (AA)
Description: EA: Ten points will be used, including GV24 (Shenting), GV20 (Baihui), EX-HN1 (Sishenchong), PC6 (Neiguan), CV12 (Zhongwan), CV4 (Guanyuan), ST25 (Tianshu), ST36 (Zusanli), SP6 (Sanyinjiao), KI3 (Taixi).~AA: Vaccaria seeds will be embedded by acupuncturists on three auricular points (Shenmen, Sympathetic and Heart) and maintained between EA treatments.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Electroacupuncture (SE) and Sham Auricular Acupressure (SA)
Description: SE: The sham acupuncture treatment procedure, including the acupoint selection principle, sterilization procedure and treatment schedule, will be the same as in the acupuncture treatment group, except that sham points 1 to 2 cm exterior and inferior to the real points will be used, and no needle penetration or electric stimulation will be performed.~SA: Three sham auricular points in the helix region (HX7, HX8, HX9) will be selected. Instead of Vaccaria seeds, soft Junci Medulla (1 to 2 mm in length, dyed black) will be used to mimic real AA with no pressure.
Study: NCT04538716

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transconjunctival lower blepharoplasty
Description: transconjunctival lower blepharoplasty associated with stromal vascular fraction gel (SVF-gel)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transconjunctival lower blepharoplasty
Description: transconjunctival lower blepharoplasty associated with stromal vascular fraction gel (SVF-gel)
Study: NCT01985776

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise intervention
Description: Functional stabilisation exercise for the trunk.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise and e-stim
Description: Functional stabilisation exercise for the trunk and electrical stimulation at the same time.
Study: NCT03744494

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral simple orchidectomy (BSO)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Subcapsular Orchidectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Epididymal-sparing Orchidectomy
Study: NCT00483574

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, IM at age 9 and 12 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles-mumps-rubella-varicella vaccine
Description: 0.5 mL, intramuscular at 12 months of age

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Measles-mumps-rubella-varicella vaccine
Description: 0.5 mL, intramuscular at 12 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Routine paediatric vaccine - Pneumococcal conjugate (PCV)
Description: 0.5 mL, Intramuscular at age 12 months

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Routine paediatric vaccine - Pneumococcal conjugate (PCV)
Description: 0.5 mL, Intramuscular at age 12 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Routine paediatric vaccine - Hepatitis A
Description: 0.5 mL, Intramuscular at age 12 months

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Routine paediatric vaccine - Hepatitis A
Description: 0.5 mL, Intramuscular at age 12 months
Study: NCT01516060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: 400mg qd; 2 x 200mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: 600mg qd; 3 x 200mg qd
Study: NCT01761461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1, oxaliplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TS-1, oxaliplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TS-1, oxaliplatin
Study: NCT00707252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyphenon E
Description: Patients will be assigned to 3 sequential cohorts of three different dose levels of Polyphenon E (providing 200, 400 and 800mg of Polyphenon E given once daily) in a step-wise manner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: All patients will also receive Erlotinib 150mg po/day from Day 1.
Study: NCT04310241

Intervention type: BEHAVIORAL
Intervention: Patching therapy, Glasses
Description: Patching, glasses and strabismus surgery are commonly employed measures in treatment of amblyopia and strabismus.
Study: NCT00457795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brimonidine 0.1% (Alphagan® P)
Description: Brimonidine 0.1%, 1 drop three-times daily for 4 weeks
Study: NCT01001195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-210669 ophthalmic solution, 0.1%
Description: One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-210669 ophthalmic solution, 0.075%
Description: One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-210669 ophthalmic solution, 0.05%
Description: One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost ophthalmic solution 0.03%
Description: One drop of bimatoprost ophthalmic solution 0.03% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
Study: NCT01407965

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microdialysis catheter
Description: Placing of microdialysis catheter in fatty tissue and in the peritoneal cavity

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microdialysis catheter
Description: Placing of microdialysis catheter in fatty tissue and in the peritoneal cavity
Study: NCT03018756

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate
Description: 100 mcg fentanyl citrate will be inhaled via nebulizer.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline solution will be inhaled via nebulizer
Study: NCT02293876

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: LACRIBELL®
Description: Hypromellose and dextran based eyedrop, used in the treatment of dry eye.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: LIPOSIC®
Description: Carbomer and Sorbitol based gel, used in the treatment of dry eye.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Glad wrap
Description: A clear plastic wrap occluding eye and orbital area, turning the space into a moisture chamber.
Study: NCT00968591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study: NCT01352390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planning Prompt
Description: A prompt to have their child their health test reminder mailing to color
Study: NCT02665754

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ILIT with extract of causal allergen
Description: 0.5 ml of allergen extract from D. farinae, D. pteronyssinus, cat, and/or dog for allergen specific immunotherapy (Tyrosine S, Allergy Therapeutic, UK) will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ILIT with normal saline
Description: 0.5 ml of normal saline will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication for allergic rhinitis
Description: Subjects are requested to administer oral antihistamine (cetirizine) or nasal glucocorticosteroid (ciclesonide) as rescue medication for allergic rhinitis in accordance with severity and frequency of allergic rhinitis symptoms according to Allergic Rhinitis and its Impact on Asthma (ARIA) guideline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue medication for allergic rhinitis
Description: Subjects are requested to administer oral antihistamine (cetirizine) or nasal glucocorticosteroid (ciclesonide) as rescue medication for allergic rhinitis in accordance with severity and frequency of allergic rhinitis symptoms according to Allergic Rhinitis and its Impact on Asthma (ARIA) guideline.
Study: NCT01377857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monetary Incentive
Description: $1, $5, or $10 incentive

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monetary Incentive
Description: $1, $5, or $10 incentive

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monetary Incentive
Description: $1, $5, or $10 incentive

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monetary Incentive
Description: $1, $5, or $10 incentive

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire Timing
Description: Timing of the questionnaire--either before or after testing is offered.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire Timing
Description: Timing of the questionnaire--either before or after testing is offered.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire Timing
Description: Timing of the questionnaire--either before or after testing is offered.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Test Offering
Description: HIV Test will be offered as opt-in, opt-out, or active choice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Test Offering
Description: HIV Test will be offered as opt-in, opt-out, or active choice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Test Offering
Description: HIV Test will be offered as opt-in, opt-out, or active choice.
Study: NCT00350935

Intervention type: PROCEDURE
Intervention: fMRI
Description: One 30 minute session

Intervention type: PROCEDURE
Intervention: fMRI
Description: One 30 minute session
Study: NCT03585595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood pressure lowering strategy
Description: The proposed trial will test a treatment strategy of different systolic BP goals and not specific medications. It remains unclear whether a particular class of antihypertensive drug offers an advantage over others in secondary stroke prevention. Therefore, the BP treatment protocol is flexible in terms of the choice and doses of antihypertensive medications. However, we will emphasize the use of drugs best demonstrated to be effective in lowering CVD in outcome trials and recommended in current clinical guidelines.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood pressure lowering strategy
Description: The proposed trial will test a treatment strategy of different systolic BP goals and not specific medications. It remains unclear whether a particular class of antihypertensive drug offers an advantage over others in secondary stroke prevention. Therefore, the BP treatment protocol is flexible in terms of the choice and doses of antihypertensive medications. However, we will emphasize the use of drugs best demonstrated to be effective in lowering CVD in outcome trials and recommended in current clinical guidelines.
Study: NCT03046732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementing Explore Transplant Education
Description: The Explore Transplant Ontario (ETO) education program
Study: NCT01404767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Baseline treatment consists of a bolus of 500ug/kg/min followed by an infusion of 50ug/kg/min for 4 minutes and titrating in increment of 50ug/kg/min up to a maximum of 300ug/kg/min to maintain a HR within 10% of the target HR (≤ 70 bpm), which is 70± 7 bpm.
Study: NCT01352390

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Condition
Description: A basic reminder mailing will prompt each subject to get a health test as specified on the mailing
Study: NCT01404767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: The night and morning before surgery, the patients in the metoprolol arm will receive their standard dose of beta blocker metoprolol.These patients will receive their daily beta blockers orally or via nasogastric tube postoperatively if they are NPO (Group A).
Study: NCT01709825

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic- Bifidobacterium Bifidum
Description: Bifidobacterium bifidum R0071 will be taken as a capsule once daily for 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Sugar Pill (Sucrose) will be taken as a capsule once daily for 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic- Lactobacillus helveticus
Description: Lactobacillus helveticus R0052 will be taken as a capsule once daily for 6 weeks.
Study: NCT04019691

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mix-and-Match
Description: Phacoemulsification and implantation of Tecnis ZKB00 multifocal IOL with +2.75 D add power (Abbott Medical Optic Inc., Santa Ana, CA) in the dominant eye, and a Tecnis ZLB00 multifocal IOL with +3.25 D add power (Abbott Medical Optics Inc.) in the non-dominant eye.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EDOF
Description: Phacoemulsification and implantation of Tecnis Symfony ZXR00 trifocal IOLs (Abbot Medical Optics Inc.) in both eyes.
Study: NCT01709825

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic- Bifidobacterium longum ss. Infantis R0033
Description: Bifidobacterium longum ss. Infantis R0033 (Supplement C) will be taken as a capsule once daily for 6 weeks.
Study: NCT04413786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin treatment
Description: intranasal administration of oxytocin (24IU)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo treatment
Description: intranasal administration of placebo (24IU)
Study: NCT01942993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib will be administered at the FDA approved dose of 960 mg approximately 12 hours apart with or without a meal. Vemurafenib is provided at 240-mg film-coated tablets packed in bottles for oral administration. Vemurafenib should be swallowed whole with a glass of water and the medication should not be chewed or crushed. Management of symptomatic adverse events may require dose reductions, treatment interruptions, or treatment discontinuation. Dose reductions below 480 mg twice daily are not recommended.
Study: NCT02317003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention PPIL

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control OR
Study: NCT03867240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin (10 mg/kg up to 600 mg) will be given 30 minutes prior to being transported to the operating room. The gabapentin will be in the standard liquid with a concentration of 250mg/5mL. Starting postoperative day 1, patients in the experimental group will receive gabapentin three times daily. Dose of gabapentin will be 100 mg for patients \<50 kg and 200 mg for patients \> 50 kg. Gabapentin will be continued for 5 days postoperatively. If patients are discharged prior to postoperative day 5, they will be provided with gabapentin for the remainder of their doses upon discharge.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given 30 minutes prior to being transported to the operating room. Placebo will be identically appearing to gabapentin. Starting postoperative day 1, control group will receive placebo medication at the same interval with the appropriate number of capsules or liquid for their weight to match the experimental group. It will be continued for 5 days postoperatively. If patients are discharged prior to postoperative day 5, they will be provided with placebo for the remainder of their doses upon discharge.
Study: NCT03526068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SafeZoneUVC
Description: SafeZoneUVC® uses a Krypton Chloride (Kr-Cl) excimer lamp as its light source. The Kr-Cl excimer lamp emits UVC light having a main wavelength of 222 nm when the Kr-Cl exciplex is deactivated to non-excited state molecule in the lamp. This 222 nm UVC light can inactivate bacteria, while the Kr-Cl excimer lamp also emits UVC light having a wavelength of 230 nm or more. SafeZoneUVC® effectively eliminates UVC light with a wavelength of 230 nm or more by incorporating an appropriate optical filter inside the unit and also utilizing an opaque guide to ensure that light is not dispersed beyond the target area.
Study: NCT02764593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Anti-PD-1 targeted immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Anti-PD-1 targeted immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Anti-PD-1 targeted immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Anti-PD-1 targeted immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Anti-cancer alkylating agent
Study: NCT01933490

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal
Study: NCT01314131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulation group
Description: Patients living in nursing home can be enrolled in the study by giving their verbal consent. The trial lasts two weeks for each patients and it will be performed in three parts :~* a cognitive and behaviour assessment : MMSE, BREF, NPI, IA~* an interest questionnaire for patients. It contains 40 questions about activities.~* the intervention : patients will be propose 5 activities. 4 of them are activities that patients are interested in. Each activity have to last 15 minutes and the stimulation is measured by a scale named Observational Measurement of Engagement .
Study: NCT04030026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAL ER
Description: Participants will receive NAL ER 27 mg QD, 27 mg BID, 54 mg BID, 108 mg BID, 162 mg BID over a 3 week period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAL ER
Description: Participants will receive NAL ER 27 mg QD, 27 mg BID, 54 mg BID, 108 mg BID, 162 mg BID over a 3 week period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo tablet (matching NAL ER BID) over a 3 week period.
Study: NCT04019691

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trifocal
Description: Phacoemulsification and implantation of FineVision PodFT IOLs (PhysIOL SA) in both eyes.
Study: NCT04030026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo tablet (matching NAL ER BID) over a 3 week period.
Study: NCT01678378

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHARP Intervention
Description: Providers and staff located in high school school health centers (i.e., nurse practitioners, nurses,physicians, health educators, medical assistants) will be trained to address adolescent relationship abuse with school health center clients using knowledge, skills, and resources gained through the SHARP Intervention training. The training includes strategies to help youth recognize adolescent relationship abuse among themselves and their peers, to learn strategies to increase safety (harm reduction), and to utilize adolescent relationship abuse-related resources.
Study: NCT00991653

Intervention type: PROCEDURE
Intervention: Fasting blood sample.
Description: Fasting blood sample taken following informed consent for genotyping, glucose and insulin levels.
Study: NCT04663503

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Depending on the age, there will be two components of the exercise program completed by the patients. The first component will be strengthening exercises. The second component will be endurance activities. This will be administered by the physical therapist
Study: NCT00855244

Intervention type: OTHER
Group type: OTHER
Intervention: Diagnostic exams
Description: Growth hormone stimulation testing, oral glucose tolerance test, hyperinsulinemic euglycemic clamp
Study: NCT03810196

Intervention type: DEVICE
Group type: OTHER
Intervention: CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback
Description: Peripheral stem cell (PSC) product will be processed using the CliniMACS device for TCRαβ and T cell depletion. Approximately 10% of the PSCs will undergo CD45RA depletion and cryopreservation. Patients will receive CD45RA depleted infusion after the TCRab PSCT.

Intervention type: DEVICE
Group type: OTHER
Intervention: CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback
Description: Peripheral stem cell (PSC) product will be processed using the CliniMACS device for TCRαβ and T cell depletion. Approximately 10% of the PSCs will undergo CD45RA depletion and cryopreservation. Patients will receive CD45RA depleted infusion after the TCRab PSCT.
Study: NCT02539901

Intervention type: BEHAVIORAL
Intervention: Evaluation of the detection of non-linguistic sounds
Description: Evaluation of the detection of non-linguistic sounds (sound room)

Intervention type: BEHAVIORAL
Intervention: Evaluation of the detection of non-linguistic sounds
Description: Evaluation of the detection of non-linguistic sounds (sound room)

Intervention type: BEHAVIORAL
Intervention: Free hearing test categorization
Description: Free hearing test categorization evaluation

Intervention type: BEHAVIORAL
Intervention: Free hearing test categorization
Description: Free hearing test categorization evaluation

Intervention type: BEHAVIORAL
Intervention: Early Social Communication Scale (ECSP)
Description: Early Social Communication Scale (ECSP) evaluation

Intervention type: BEHAVIORAL
Intervention: psychomotor infancy development scale

Intervention type: BEHAVIORAL
Intervention: NEPSY (two domains: memory and learning and attention and executive functions).
Description: NEPSY evaluation
Study: NCT02191371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Patients are randomized to receive intravenous anesthetic (propofol) or inhalational anesthetic (desflurane) as a maintenance anesthetic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desflurane
Description: Patients are randomized to receive intravenous anesthetic (propofol) or inhalational anesthetic (desflurane) as a maintenance anesthetic.